Abstract: The integrated automated cell culture device includes a main body, a cover, a connection seat, a gas module, a temperature module, at least one slide track, and a clamping member. The main body encloses a culture room for receiving a culture bag. The cover is disposed on the opening of the culture room. The connection seat is received in a receiving slot of the main body and is adapted for a pipe to penetrate. The gas module detects the carbon dioxide's concentration and selectively injects gas into the culture room. The temperature module detects the temperature in the culture room and selectively heats the culture room. The slide track is disposed on the bottom of the culture room. The clamping member is slidably disposed on the slide track and clamps the culture bag to make the fluid in the culture bag move to one side of the culture bag.

Abstract: The invention is directed to dimeric fusion proteins and virus-like particles comprising such dimeric fusion proteins. These dimeric fusion proteins comprise an antigen or antigenic fragment carried between two viral structural proteins or fragments thereof, with or without linkers, in a manner that, relative to traditional monomeric platforms, minimizes steric hindrance among the antigen or antigenic fragment and the viral structural proteins or fragments thereof. This novel design provides for multivalent vaccines and enhanced immunogenicity. The invention also relates to nucleic acids encoding such dimeric fusion proteins and host cells comprising such nucleic acids. The invention further relates to pharmaceutical compositions comprising the dimeric fusion proteins and/or virus-like particles of the invention, and methods of prevention or treatment using such compositions.

Abstract: The invention is directed to dimeric fusion proteins and virus-like particles comprising such dimeric fusion proteins. These dimeric fusion proteins comprise an antigen or antigenic fragment carried between two viral structural proteins or fragments thereof, with or without linkers, in a manner that, relative to traditional monomeric platforms, minimizes steric hindrance among the antigen or antigenic fragment and the viral structural proteins or fragments thereof. This novel design provides for multivalent vaccines and enhanced immunogenicity. The invention also relates to nucleic acids encoding such dimeric fusion proteins and host cells comprising such nucleic acids. The invention further relates to pharmaceutical compositions comprising the dimeric fusion proteins and/or virus-like particles of the invention, and methods of prevention or treatment using such compositions.